Status:
RECRUITING
1726-nm Laser for Acne Inversa (Hidradenitis Suppurativa)
Lead Sponsor:
Wynn Medical Center
Conditions:
Hidradenitis Suppurativa (HS)
Eligibility:
All Genders
18-60 years
Phase:
PHASE1
Brief Summary
Hidradenitis suppurativa (HS) is a long-lasting skin condition that causes painful lumps, abscesses, and tunnels in areas such as the armpits and groin. HS begins around the hair follicle; when the fo...
Detailed Description
Hidradenitis suppurativa (HS) is a chronic, relapsing inflammatory disorder of the hair follicle characterized by painful nodules, abscesses, and dermal tunnels that cluster in intertriginous sites. C...
Eligibility Criteria
Inclusion
- Adults 18-60 years; any sex; Fitzpatrick I-VI.
- Clinical HS, Hurley I-II (Investigator confirmed).
- At least one inflammatory nodule in a paired, bilateral region (axilla, groin/inguinal, inframammary, inner thigh, or buttock) within 4 weeks prior to baseline.
- Able to read/speak English/Chinese/Spanish/Vietnamese and sign consent.
- Willing/able to comply with visits, pre/post-care, standardized photography.
- Agree to avoid new HS procedures/therapies in study areas through Week 24.
- No laser contraindication; agrees to shave/clip hair before treatments.
- Optional translational cohort: willing to undergo 4-mm punch biopsy at baseline and Week 16 from the randomized regions (separate consent).
Exclusion
- Hurley III (extensive sinus tracts).
- No qualifying nodule(s) in paired bilateral regions in past 4 weeks.
- Prior device/procedure to target areas within 3 months (chemical peel, dermabrasion, microneedling/RF, other lasers/LBB, cryo/chemo-destruction)
- Had Botulinum toxin in target areas within 3 months or planned during study.
- Had systemic retinoid (e.g., isotretinoin) within 3 months.
- Photosensitizing meds that, in PI's judgment, materially increase risk and cannot be held.
- Pregnancy/breastfeeding/plans to conceive during study.
- Active infection, still healing wounds (investigator judgment) in target areas.
- History of keloids/hypertrophic scars, radiation to target areas, malignancy in target areas, diagnosed immunodeficiency, uncontrolled coagulation disorder or therapeutic anticoagulation that cannot be safely managed.
- Excessive tanning or inability to avoid tanning.
- Any condition (medical/mental) or prisoner status that in PI's opinion compromises safety or adherence.
Key Trial Info
Start Date :
September 15 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT07155239
Start Date
September 15 2025
End Date
December 31 2026
Last Update
September 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wynn Medical Center Rheumatology/Dermatology
Rosemead, California, United States, 91770